Market Newsdesk

Deadline Reminder: Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Velodyne Lidar, Inc. (VLDR)

BENSALEM, Pa.–(BUSINESS WIRE)–
Law Offices of Howard G. Smith reminds investors of the upcoming May 3, 2021 deadline to file a lead plaintiff motion in the case filed on behalf of investors who purchased Velodyne Lidar, Inc. (“Velodyne” or “the Company”) (NASDAQ: VLDR) securities between November 9, 2020 and February 19, 2021, inclusive (the “Class Period”).

Investors suffering losses on their Velodyne investments are encouraged to contact the Law Offices of Howard G. Smith to discuss their legal rights in this class action at 888-638-4847 or by email to [email protected].

On February 22, 2021, Velodyne announced that the Board had “removed David Hall as Chairman of the Board and terminated Marta Hall’s employment as Chief Marketing Officer of the Company” after the Audit Committee’s investigation “concluded that Mr. Hall and Ms. Hall each behaved inappropriately with regard to certain Board and Company processes, and failed to operate with respect, honesty, integrity, and candor in their dealings with Company officers and directors.” In addition, the Company announced that Velodyne’s Board formally censured Mr. Hall and Ms. Hall, but that they would remain directors of Velodyne.

On this news, Velodyne’s common stock fell $3.14, or approximately 15%, to close at $17.97 per share on February 22, 2021, on unusually heavy trading volume. Additionally, Velodyne’s warrants fell $1.47, or approximately 20%, to close at $5.90 per warrant on February 22, 2021.

The complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, Defendants failed to disclose to investors: (1) that certain of Velodyne’s directors had failed to operate with respect, honesty, integrity, and candor in their dealings with the Company’s officers and directors; (2) that the Company was investigating the foregoing matters; and (3) that, as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects were materially false and misleading and/or lacked reasonable basis at all relevant times.

If you purchased or otherwise acquired Velodyne securities during the Class Period, you may move the Court no later than May 3, 2021 to ask the Court to appoint you as lead plaintiff if you meet certain legal requirements. To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action. If you wish to learn more about this class action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Howard G. Smith, Esquire, of Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020, by telephone at (215) 638-4847, toll-free at (888) 638-4847, or by email to [email protected], or visit our website at www.howardsmithlaw.com.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210305005076/en/

Law Offices of Howard G. Smith

Howard G. Smith, Esquire

215-638-4847

888-638-4847

[email protected]

www.howardsmithlaw.com

KEYWORDS: Pennsylvania United States North America

INDUSTRY KEYWORDS: Legal Professional Services

MEDIA:

March 5, 2021 11:33 am

INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Aquestive Therapeutics, Inc. (AQST) Investors

INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Aquestive Therapeutics, Inc. (AQST) Investors

BENSALEM, Pa.–(BUSINESS WIRE)–
Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased Aquestive Therapeutics, Inc. (“Aquestive” or the “Company”) (NASDAQ: AQST) securities between December 2, 2019 and September 25, 2020, inclusive (the “Class Period”). Aquestive investors have until April 30, 2021 to file a lead plaintiff motion.

Investors suffering losses on their Aquestive investments are encouraged to contact the Law Offices of Howard G. Smith to discuss their legal rights in this class action at 888-638-4847 or by email to [email protected].

Aquestive is a specialty pharmaceutical company. Its most advanced proprietary product candidate is Libervant, a buccal soluble film formulation of diazepam for the treatment of recurrent epileptic seizures.

On December 2, 2019, Aquestive announced the completion of the rolling submission of a New Drug Application (“NDA”) to the U.S. Food and Drug Administration (“FDA”) for Libervant Buccal Film for the management of seizure clusters.

On September 25, 2020, Aquestive announced receipt of a Complete Response Letter (“CRL”) from the FDA stating that the NDA would not be approved in its current form. According to the CRL, “in a study submitted by the Company with the NDA, certain weight groups showed a lower drug exposure level than desired.” The Company stated that it “intends to provide to the FDA additional information on PK modeling to demonstrate that dose adjustments will obtain the desired exposure levels.”

On this news, Aquestive’s stock price fell $2.64 per share, or approximately 35%, to close at $4.97 per share on September 28, 2020.

The complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, Defendants failed to disclose to investors that: (1) data included in the Libervant NDA submission showed a lower drug exposure level than desired for certain weight groups; (2) the foregoing significantly decreased the Libervant NDA’s approval prospects; (3) as a result, it was foreseeable that the FDA would not approve the Libervant NDA in its current form; and (4) as a result, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis at all relevant times.

If you purchased Aquestive securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Howard G. Smith, Esquire, of Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020, by telephone at (215) 638-4847, toll-free at (888) 638-4847, or by email to [email protected], or visit our website at www.howardsmithlaw.com.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210305005072/en/

Law Offices of Howard G. Smith

Howard G. Smith, Esquire

215-638-4847

888-638-4847

[email protected]

www.howardsmithlaw.com

KEYWORDS: Pennsylvania United States North America

INDUSTRY KEYWORDS: Legal Professional Services

MEDIA:

March 5, 2021 11:33 am

Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against 9F Inc. (JFU)

LOS ANGELES, March 05, 2021 (GLOBE NEWSWIRE) — Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming March 22, 2021 deadline to file a lead plaintiff motion in the case filed on behalf of investors who purchased or otherwise acquired 9F Inc. (“9F” or the “Company”) (NASDAQ: JFU) securities: (a) pursuant and/or traceable to the registration statement and related prospectus in connection with the Company’s August 14, 2019 initial public offering (the “IPO” or “Offering”); and/or (b) between August 14, 2019 and September 29, 2020, inclusive (the “Class Period”).

If you suffered a loss on your 9F investments or would like to inquire about potentially pursuing claims to recover your loss under the federal securities laws, you can submit your contact information at https://www.glancylaw.com/cases/9f-inc/. You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at [email protected] to learn more about your rights.

In August 2019, 9F completed its initial public offering (“IPO”), selling approximately 8.9 million American Depositary Shares at $9.50 a share.

On September 27, 2019, 9F reported its second quarter 2019 financial results for the period that ended prior to the IPO. The Company stated that its net accounts receivable increased from RMB277 million as of March 31, 2019 to RMB 858 million as of June 30, 2019, a 210% sequential increase.

On this news, 9F shares fell $0.59, or 5%, to close at $10.35 per ADS on September 27, 2019.

On December 5, 2019, 9F reported its third quarter 2019 financial results for the quarter during which the IPO had been conducted. The Company stated that its net accounts receivables had increased more than ten-fold from RMB180 million as of December 31, 2018 to RMB1.9 billion as of September 30, 2019.

On this news, 9F shares fell $0.50, or nearly 5%, over two consecutive trading sessions to close at $9.60 per ADS on December 6, 2019.

On June 12, 2020, 9F revealed an ongoing dispute with Property and Casualty Company Limited (“PICC”) involving RMB2.2 billion in unpaid service fees. The Company stated that RMB1.4 billion in service fees that had previously been recorded as accounts receivable were now recognized as fully impaired.

On June 17, 2020, 9F described the devastating consequences of the Company’s dispute with PICC, including that the two entities “are pursuing legal actions against each other” and that 9F sought damages of approximately RMB2.3 billion from PICC to cover the outstanding service fees and related late payment losses. Moreover, 9F had “suspended [its] cooperation with PICC on new loans under [its] direct lending program since December 2019,” causing total net revenues to decrease by 54.4% year-over-year.

On this news, 9F shares fell $0.31 per ADS, or nearly 5%, to close at $6.00 per ADS on June 17, 2020.

On June 24, 2020, the Company reported a valuation allowance for the accounts receivable from PICC of more than $1.4 billion.

On this news, 9F shares fell $0.57, or 14%, to close at $4.05 per ADS on June 25, 2020.

On September 29, 2020, 9F announced its unaudited financial results for the first half of 2020 ended June 30, 2020. The Company disclosed that its loan origination volume had fallen over 90%, the number of active borrowers utilizing their platform had decreased over 80% and the Company’s total net revenues had plummeted over 60% during the first half of 2020 as compared to the latter half of 2019.

On this news, 9F shares fell $0.20, or 18%, to close at $0.91 per ADS on September 29, 2020, thereby damaging investors. Since the IPO, 9F ADSs have traded as low as $1.40 per ADS, an 85% decline from the IPO price.

The complaint filed alleges that Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, Defendants failed to disclose to investors that: (1) the purported value and benefits of the Company’s financial institution partners and its tri-party cooperation business model did not in fact exist and/or were materially overstated, given that 9F and PICC had been engaged in an ongoing contractual dispute regarding payment of service fees under the Cooperation Agreement; (2) the collectability of service fees owed to 9F by PICC under the Cooperation Agreement was in doubt and at serious risk of non-payment; (3) there was a significant risk that PICC would no longer provide credit insurance and guarantee protection to investors and institutional funding partners; and (4) as a result of the foregoing, the Company’s platform, business model, reputation and financial results had been materially impaired.

If you purchased or otherwise acquired 9F securities pursuant/traceable to the IPO and/or during the Class Period, you may move the Court no later than March 22, 2021 to request appointment as lead plaintiff in this putative class action lawsuit. To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action. If you wish to learn more about this class action, or if you have any questions concerning this announcement or your rights or interests with respect to the pending class action lawsuit, please contact Charles Linehan, Esquire, of GPM, 1925 Century Park East, Suite 2100, Los Angeles, California 90067 at 310-201-9150, Toll-Free at 888-773-9224, by email to [email protected], or visit our website at www.glancylaw.com. If you inquire by email please include your mailing address, telephone number and number of shares purchased.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contacts

Glancy Prongay & Murray LLP, Los Angeles
Charles Linehan, 310-201-9150 or 888-773-9224
[email protected]
www.glancylaw.com

March 5, 2021 11:33 am

Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Immunovant, Inc. f/k/a Health Sciences Acquisitions Corporation (IMVT)

LOS ANGELES, March 05, 2021 (GLOBE NEWSWIRE) — Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming April 20, 2021 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Immunovant, Inc. f/k/a Health Sciences Acquisitions Corporation (“HSAC”, “Immunovant”, or the “Company”) (NASDAQ: IMVT) securities between October 2, 2019 and February 1, 2021, inclusive (the “Class Period”).

If you suffered a loss on your Immunovant investments or would like to inquire about potentially pursuing claims to recover your loss under the federal securities laws, you can submit your contact information at https://www.glancylaw.com/cases/immunovant-inc/. You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at [email protected] to learn more about your rights.

On September 29, 2019, HSAC entered into an agreement with Immunovant Sciences Ltd. (“Legacy Immunovant”) to effect a merger between the two entities (the “Merger”).

Immunovant is developing IMVT-1401, a novel fully human monoclonal antibody, which is Phase IIa clinical trials for the treatment of myasthenia gravis (“MG”) and thyroid eye disease (“TED”). The Company has also completed initiation of Phase II clinical trials of IMVT-1401 for the treatment of warm autoimmune hemolytic anemia (“WAIHA”).

On February 2, 2021, the Company issued a press release “announc[ing] a voluntary pause of dosing in its ongoing clinical trials for IMVT-1401.” The Company also disclosed that it “has become aware of a physiological signal consisting of elevated total cholesterol and LDL [low-density lipoproteins] levels in IMVT-1401-treated patients” and “[o]ut of an abundance of caution, the Company has decided to voluntarily pause dosing in ongoing clinical studies in both TED and in [WAIHA], in order to inform patients, investigators, and regulators as well as to modify the monitoring program.”

On this news, the Company’s stock price fell $18.22 per share, or 42.08%, to close at $25.08 per share on February 2, 2021, thereby injuring investors.

The complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, Defendants failed to disclose to investors that: (1) HSAC had performed inadequate due diligence into Legacy Immunovant prior to the Merger, and/or ignored or failed to disclose safety issues associated with IMVT-1401; (2) IMVT-1401 was less safe than the Company had led investors to believe, particularly with respect to treating TED and WAIHA; (3) the foregoing foreseeably diminished IMVT-1401’s prospects for regulatory approval, commercial viability, and profitability; and (4) as a result, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis at all relevant times.

If you purchased or otherwise acquired Immunovant securities during the Class Period, you may move the Court no later than April 20, 2021 to request appointment as lead plaintiff in this putative class action lawsuit. To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action. If you wish to learn more about this class action, or if you have any questions concerning this announcement or your rights or interests with respect to the pending class action lawsuit, please contact Charles Linehan, Esquire, of GPM, 1925 Century Park East, Suite 2100, Los Angeles, California 90067 at 310-201-9150, Toll-Free at 888-773-9224, by email to [email protected], or visit our website at www.glancylaw.com. If you inquire by email please include your mailing address, telephone number and number of shares purchased.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contacts

Glancy Prongay & Murray LLP, Los Angeles
Charles Linehan, 310-201-9150 or 888-773-9224
[email protected]
www.glancylaw.com

March 5, 2021 11:33 am

Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against EHang Holdings Limited (EH)

Shareholders with $10,000 losses or more are encouraged to contact the firm

LOS ANGELES, March 05, 2021 (GLOBE NEWSWIRE) — Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming April 19, 2021 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired EHang Holdings Limited (“EHang” or the “Company”) (NASDAQ: EH) American Depositary Shares (“ADSs”) between December 12, 2019 and February 16, 2021, inclusive (the “Class Period”).

If you suffered a loss on your EHang investments or would like to inquire about potentially pursuing claims to recover your loss under the federal securities laws, you can submit your contact information at https://www.glancylaw.com/cases/ehang-holdings-limited/. You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at [email protected] to learn more about your rights.

On February 16, 2021, analyst Wolfpack Research published a research report entitled “EHang: A Stock Promotion Destined to Crash and Burn.” Citing “extensive evidence” including “behind-the-scenes photographs, recorded phone calls, and videos of on-site visits to EH’s various facilities,” the report alleged that EHang is “an elaborate stock promotion, built on largely fabricated revenues based on sham sales contracts with a customer [Shanghai Kunxiang Intelligent Technology Co., Ltd.] who appears to us to be more interested in helping inflate the value of its investment in EH . . . than about buying its products.” Wolfpack Research also noted that “in just 14 months as a publicly traded company, EH’s PR team has put out 50 press releases . . . . However, EH’s constant stream of press releases are easily proven untrue.” Finally, the report alleged that Wolfpack Research “obtained Chinese court records which show that EH’s ADRs may already be in serious jeopardy due to legal issues in China.”

On this news, the Company’s share price fell $77.79, or approximately 62.7%, to close at $46.30 per share, thereby injuring investors.

The complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, Defendants failed to disclose to investors that: (1) the Company’s purported regulatory approvals in Europe and North America for its EH216 were for use as a drone, and not for carrying passengers; (2) its relationship with its purported primary customer is a sham; (3) EHang has only collected on a fraction of its reported sales since its ADS began trading on NASDAQ in December 2019; (4) the Company’s manufacturing facilities were practically empty and lacked evidence of advanced manufacturing equipment or employees; and (5) as a result, Defendants’ statements about its business, operations, and prospects were materially false and misleading and/or lacked reasonable basis at all relevant times.

If you purchased or otherwise acquired EHang ADSs during the Class Period, you may move the Court no later than April 19, 2021 to request appointment as lead plaintiff in this putative class action lawsuit. To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action. If you wish to learn more about this class action, or if you have any questions concerning this announcement or your rights or interests with respect to the pending class action lawsuit, please contact Charles Linehan, Esquire, of GPM, 1925 Century Park East, Suite 2100, Los Angeles, California 90067 at 310-201-9150, Toll-Free at 888-773-9224, by email to [email protected], or visit our website at www.glancylaw.com. If you inquire by email please include your mailing address, telephone number and number of shares purchased.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contacts

Glancy Prongay & Murray LLP, Los Angeles
Charles Linehan, 310-201-9150 or 888-773-9224
[email protected]
www.glancylaw.com

March 5, 2021 11:30 am

IIROC Trading Halt – DFLY

Canada NewsWire

VANCOUVER, BC, March 5, 2021 /CNW/ – The following issues have been halted by IIROC:

Company: Draganfly Inc.

CSE Symbol: DFLY

All Issues: No

Reason: Single-Stock Circuit Breaker

Halt Time (ET): 11:20:47 AM

IIROC can make a decision to impose a temporary suspension (halt) of trading in a security of a publicly-listed company. Trading halts are implemented to ensure a fair and orderly market. IIROC is the national self-regulatory organization which oversees all investment dealers and trading activity on debt and equity marketplaces in Canada.

SOURCE Investment Industry Regulatory Organization of Canada (IIROC) – Halts/Resumptions

March 5, 2021 11:28 am

ProStar Rings the Opening Bell on the Toronto Stock Exchange

PR Newswire

GRAND JUNCTION, Colo., March 5, 2021 /PRNewswire/ — ProStar Holdings Inc (“ProStar” or the “Company”) (TSXV: MAPS) is pleased to report that the Company’s CEO and Founder, Page Tucker and the ProStar team joined Arne Gulstene, Head, Company Services, TMX Group, to celebrate the Company’s listing on the Toronto Stock Exchange (TSX) Venture Exchange by ringing the bell to open the market today.

ProStar™ is a world leader in Precision Mapping Solutions™. The Company’s flagship product, PointMan^®, improves the business operations of industries involved in the construction, maintenance, upgrade and repair of surface and subsurface infrastructure. ProStar’s clients include Fortune 500 construction firms, government agencies, energy companies, and engineering and surveying firms in North America and Europe.

“For any company it would be considered an honor and a privilege to ring the opening bell, and today is no exception,” said Page Tucker, CEO and founder of ProStar. “This occasion marks a major milestone for us that required a great deal of effort and commitment from so many stakeholders as well as the TMX and albeit a virtual event due to the pandemic, it is still a momentous occasion.”

What You Should Know About ProStar (TSXV: MAPS)(FSE: 5D00)

ProStar is a world leader in Precision Mapping Solutions™. ProStar’s flagship product, PointMan, is natively cloud and mobile, offered as a Software as a Solution (SaaS). ProStar’s solutions are being adopted by some of the largest entities in North America, including Fortune 500 construction firms, the largest subsurface utilities engineering (SUE) firms, and government agencies.

ProStar’s strategic partnerships are with leading geospatial technology and data collection equipment manufactures and their dealer networks, including Trimble^®(NASDAQ: TRMB), Juniper^® Systems, Vivax-Metrotech, Radiodetection^®, and Subsite^® Electronics.

The company has made a significant investment in creating a vast intellectual property portfolio that includes 19 issued patents in the United States and Canada, with more pending. The patents protect the methods and systems required to digitally capture, record, organize, manage, distribute, and display the precise location of buried utilities and pipelines.

ProStar’s Executive management team has extensive experience in both early stage and Fortune 500 companies, TSX and TSX.V listed enterprises, and in geospatial, cloud and mobile technologies. ProStar’s leadership team includes Vasa Dasan, former CTO of Sun Microsystems, Carl Lashua, previous Chief Information Officer of HSBC Canada and Europe, and Matthew Breman prior Executive for Disney.

For more information about ProStar, please visit: www.prostarcorp.com.

Contact

Alex Moore

Investor Relations Support
[email protected]
970-242-4024

Neither the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release.

Cautionary Statements Regarding Forward-Looking Information
This press release contains forward-looking information within the meaning of Canadian securities laws. Such information includes, without limitation, information regarding the terms and conditions of the Company’s future plans. Although the Company believes that such information is reasonable, it can give no assurance that such expectations will prove to be correct.

Forward-looking information is typically identified by words such as: “believe”, “expect”, “anticipate”, “intend”, “estimate”, “postulate” and similar expressions, or are those, which, by their nature, refer to future events. The Company cautions investors that any forward-looking information provided by the Company is not a guarantee of future results or performance, and that actual results may differ materially from those in forward-looking information as a result of various factors, including, but not limited to: the state of the financial markets for the Company’s securities; the state of the technology sector; recent market volatility; the COVID-19 pandemic; the Company’s ability to raise the necessary capital or to be fully able to implement its business strategies; and other risks and factors that the Company is unaware of at this time. The reader is referred to the Company’s recent Information Circular filed on SEDAR on November 20, 2020 for a more complete discussion of applicable risk factors and their potential effects, copies of which may be accessed through the Company’s issuer page on SEDAR at www.sedar.com.

The forward-looking statements contained in this press release are made as of the date of this press release. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.